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Abstract
Introduction: Severe sepsis is associated with approximately 50% mortality and accounts for tremendous healthcare
costs. Most patients require ventilatory support and propofol is commonly used to sedate mechanically ventilated
patients. Volatile anesthetics have been shown to attenuate inflammation in a variety of different settings. We therefore
hypothesized that volatile anesthetic agents may offer beneficial immunomodulatory effects during the course of
long-term intra-abdominal sepsis in rats under continuous sedation and ventilation for up to 24 hours.
Methods: Sham operation or cecal ligation and puncture (CLP) was performed in adult male Wistar rats followed by
mechanical ventilation. Animals were sedated for 24 hours with propofol (7 to 20 mg/kg/h), sevoflurane, desflurane or
isoflurane (0.7 minimal alveolar concentration each).
Results: Septic animals sedated with propofol showed a mean survival time of 12 hours, whereas >56% of all animals
in the volatile groups survived 24 hours (P <0.001). After 18 hours, base excess in propofol + CLP animals (−20.6 ± 2.0)
was lower than in the volatile groups (isoflurane + CLP: -11.7 ± 4.2, sevoflurane + CLP: -11.8 ± 3.5, desflurane + CLP -14.2 ±
3.7; all P <0.03). Plasma endotoxin levels reached 2-fold higher levels in propofol + CLP compared to isoflurane + CLP
animals at 12 hours (P <0.001). Also blood levels of inflammatory mediators (tumor necrosis factor-α, interleukin-1β,
interleukin-10, CXCL-2, interferon-γ and high mobility group protein-1) were accentuated in propofol + CLP rats
compared to the isoflurane + CLP group at the same time point (P <0.04).
Conclusions: This is the first study to assess prolonged effects of sepsis and long-term application of volatile sedatives
compared to propofol on survival, cardiovascular, inflammatory and end organ parameters. Results indicate that volatile
anesthetics dramatically improved survival and attenuate systemic inflammation as compared to propofol. The main
mechanism responsible for adverse propofol effects could be an enhanced plasma endotoxin concentration, leading to
profound hypotension, which was unresponsive to fluid resuscitation.
Introduction
Mortality due to severe sepsis has been estimated to be
between 28% and 50% [1-6]. Additionally, sepsis has a
tremendous impact on healthcare with direct costs of
$24.3 billion in 2007 in the United States alone [7]. Des-
pite continuous efforts, therapeutic approaches for sepsis
have had limited success. Recently developed drugs to
fight sepsis, such as toll-like receptor 4 antagonists [8]
and tumor necrosis factor-α (TNF-α) antibodies [9],
have also failed to decrease mortality or provide clinical
benefit in large phase III studies, and thus there remains
a need to develop better treatment strategies.
Eighty-five percent of all septic patients require inva-
sive or non-invasive ventilatory support [10]. Intubation
and mechanical ventilation are needed in about 55% to
70% of septic patients admitted to an intensive care unit
(ICU) [11], which makes sedation inevitable [12]. Based
on this fact, it is crucial to determine the effect and im-
pact of sedatives on the course of sepsis. Traditionally,
the use of benzodiazepines combined with opioids has
been the standard sedation procedure in the ICU. How-
ever, wake-up time can be considerably delayed after a
prolonged application of benzodiazepines and therefore,
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propofol has become a widely-used alternative world-
wide [13].
Beneficial immunomodulatory effects of the volatile anes-
thetic agents sevoflurane [14-20], isoflurane [15,19,21,22]
and desflurane [15,20,23] have been demonstrated in vari-
ous inflammation models. Sedation with volatile anes-
thetics in the ICU is regarded as an off-label use in many
countries [24], although they are often not utilized on a
regular basis due to technical limitations [25].
The current study is to our knowledge the first investi-
gation of the combination of mechanical ventilation and
continuous sedation over a period of 24 hours in a ro-
dent model of severe sepsis. Most sepsis studies with ro-
dents that included early mechanical ventilation were
conducted over a three to six hour period [26-28] that
likely did not model the full blown inflammatory re-
sponse observed at later time points. We hypothesized
that volatile anesthetics might reduce morbidity and
mortality by attenuating the systemic inflammatory syn-
drome provoked by cecal ligation and puncture (CLP).
This model was chosen because of the clinically relevant
condition induced by the polymicrobial infection as com-
pared to ‘sterile’ infection induced by lipopolysaccharide
[29]. To mimic ICU conditions, animals were mechanically
ventilated continuously with constant sedation induced by
either a volatile anesthetic agent (isoflurane, sevoflurane or
desflurane) or intravenously applied propofol.
Methods
Animals
After approval by the University of Illinois at Chicago
Institutional Animal Care and Use Committee (IACUC),
pathogen free male Wistar rats (351 ± 47 g) obtained
from Charles Rivers (Wilmington, MA, USA) were
housed in standard cages with free access to food and
water until the time of the experiment.
Sepsis model, monitoring and ventilation
Anesthesia was induced with ketamine/xylazine applied
intraperitoneally (100/10 mg/kg, Ketamine HCl, Hospira
Inc., Lake Forest, IL, USA; Xylazine, AnaSed, Akorn
Inc., Decatur, IL, USA). Intravenous access for fluid and
drug administration was obtained via cannulation of the
tail vein with a sterile G24 catheter (BD, Sandy, UT,
USA). After shaving and disinfecting the animal’s neck
and abdomen, the right carotid artery was dissected and
a polyethylene catheter (PE-50) was inserted for blood
pressure measurement and repetitive blood sampling,
followed by the experimental procedure for the induc-
tion of sepsis. The abdominal cavity was exposed by
midline incision in all animals. In CLP animals, the
cecum was identified and isolated, and 1/3 of the cecum
was ligated and punctured once through and through
using a 20G needle, which is known to lead to a mid-
grade sepsis [29]. In sham animals, no further manipula-
tion was performed before closure of the abdominal wall
with sutures.
After the surgical procedure in the abdominal cavity,
the trachea was exposed and a polyethylene tube (inner
diameter 2.7 mm) was inserted for mechanical ventila-
tion. Animals were ventilated in parallel using pressure-
controlled mode (PEEP 4 cmH2O, peak inspiratory pres-
sure 16 cmH2O, respiratory rate 42 to 47/minute, FiO2
0.35% to 0.45%, using Topo Small Animal Ventilator
(Kent Scientific, Torrington, CT, USA)). End-tidal CO2
was kept in the normal range (34 to 37 mmHg), adapt-
ing respiratory rate accordingly. All surgical sites were
closed with two-layers of silk sutures (subcutaneous:
running suture, skin: interrupted suture). Sterile saline
(0.9%; 0.5 ml/100 g/hour) was administered intraven-
ously for fluid replacement [30]. Arterial blood gases
were taken at 0, 6, 12, 18, and 24 hours. Blood levels of
liver and kidney markers of organ damage were assessed
at 0 and 24 hours (or at time of euthanasia). Body
temperature was maintained at 37°C using a warming
mat.
Sedation design
The animals were assigned to one of the following groups:
1) isoflurane-sham (n = 10); sham operation, 24 hour sed-
ation with isoflurane (0.7 to 0.9 vol%, isoflurane, USP,
Primal Healthcare, Andhara Pradesh, India, St. Louis,
MO); 2) propofol-sham (n = 9); sham operation, 24 hour
sedation with propofol (7 to 20 mg/kg/hour, Propoven 1%,
Fresenius Kabi, Waltham, MA, USA; median dose: 10.2
mg/kg/hour); 3) isoflurane + CLP (n = 12); CLP, 24 hour
sedation with isoflurane (0.7 to 0.9 vol%); 4) sevoflurane +
CLP (n = 12); CLP, 24 hour sedation with sevoflurane (1.3
to 1.8 vol% sevoflurane, Baxter, Deerfield, IL, USA); 5) des-
flurane + CLP (n = 11); CLP, 24 hour sedation with desflur-
ane (4.2 to 5.6 vol%, Suprane, Baxter, Deerfield, IL, USA);
and 6) propofol + CLP (n = 12); CLP, 24 hour sedation
with propofol (7 to 20 mg/kg/hour; median dose: 7.8 mg/
kg/hour).
The following supplementary groups were also stud-
ied: 1) isoflurane + intralipid + CLP (n = 9), CLP, 24 hour
sedation with isoflurane (0.7 to 0.9 vol%) plus continuous
application of intralipid (90 to 110 mg/kg/hour, intralipid
20%, Fresenius Kabi, Uppsala, Sweden); and 2) isoflurane +
CLP (12 hour) (n = 9); CLP, 12 hour sedation with isoflur-
ane (0.7 to 0.9 vol%).
Sedation was achieved by delivering 0.6 to 0.8 minimal
alveolar concentration (MAC) of the volatile agent (mea-
sured by a multi-gas analyzer, Capnomac Ultima, Datex
Ohmeda, Helsinki, Finland) or by continuous infusion
(with PHD 2000, Harvard Apparatus, Holliston, MA,
USA) of 7 to 20 mg/kg/hour propofol. To avoid contam-
ination, a new bottle of propofol was opened for each
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experiment and syringes were exchanged every eight
hours. The level of sedation was titrated to the point
where there was restoration of the toe pinch reflex while
being able to tolerate mechanical ventilation without dis-
tress. Buprenorphine (0.05 mg/kg, Buprenex, Reckitt,
Hull, England) was administered subcutaneously at the
beginning of the experiment and 12 hours after surgery
to provide proper analgesia to the animals. Additional
doses of buprenorphine were given to animals showing
any sign of not tolerating mechanical ventilation.
At the end of the experiment, the level of anesthesia
was deepened with ketamine (50 mg/kg i.v.) and bupre-
norphine (2.5 mg/kg i.v.), and animals were subsequently
euthanized by exsanguination. Plasma was preserved
and vital organs were explanted and snap-frozen in li-
quid nitrogen and stored at −80°C until further analysis.
Mortality
In the event that mean arterial blood pressure dropped
below 60 mmHg for more than 15 minutes, the level of
sedation was checked and adapted and additional fluid bo-
luses were administered (up to a cumulative dose of 1 ml/
100 g/hour). If blood pressure dropped below 50 mmHg
for more than 30 minutes and could not be corrected des-
pite additional fluid resuscitation (humane end-point cri-
teria), the animals were sacrificed for ethical reasons
according to IACUC policy.
Blood gas analysis and serum liver and kidney marker
profiles
For assessment of base-excess and oxygenation, 200 μl
of whole blood was withdrawn at five different time
points (0, 6, 12, 12, 24 hours) into heparinized tubes and
analyzed using a GEMPremier 3000 blood gas analyzer
(Model 5700, Instrumentation Laboratroy, Lexington,
MA, USA). Oxygenation index was calculated as follows:
PaO2 [mmHg]/FiO2.
Determination of liver and kidney markers (aspartate
aminotransferase (AST), alanine aminotransferase (ALT),
alkaline phosphatase (AP), bilirubin, creatinine, blood urea
nitrogen (BUN)) in serum was performed using an Olympus
AU400 chemistry analyzer (Olympus, Tokyo, Japan) in the
Biological Resources Laboratory core facility at the Uni-
versity of Illinois at Chicago.
Serum lactate measurement
L-Lactate levels were determined in serum using the
L-Lactate Assay Kit (Eton Biosciences, San Diego, CA,
USA) according to the manufacturer’s instructions.
Serum endotoxin measurement
Serum endotoxin levels were determined with the help
of the Limulus Amebocyte Lysate (LAL) QCL-1000TM
Kit (Lonza, Walkersville, MD, USA). Cross reactivity
with propofol and intralipid (intralipid 20%, Fresenius
Kabi) was excluded.
Serum cytokines
TNF-α, interleukin-1alpha (IL-1α), interleukin-1beta (IL-
1β), interleukin-6 (IL-6), interleukin-10 (IL-10), C-X-C
motif ligand two (CXCL-2) and interferon gamma (IFN-γ)
were measured in rat serum with a Luminex performance
assay (RnD Systems, Minneapolis, MN, USA) according to
the manufacturer’s instructions. Concentration of high mo-
bility group 1 protein (HMGB-1) was assessed by ELISA
(IBL international, Hamburg, Germany).
Serum creatine kinase measurement
We determined creatine kinase (CK) using Fuji Dri-Chem
4000i-Analyzer (FujiFilm, Tokyo, Japan) and Fuji Dri-
Chem Slides (CPK-P III, FujiFilm) according to the proto-
col provided by the company.
Myeloperoxidase activity in lung, liver, kidney and spleen
Myeloperoxidase (MPO) activity was determined as described
previously with minor modifications [31]. The MPOassay
buffer contained 0.34 mM H2O2 and 14.4 mM Guaiacol
(both from Sigma-Aldrich, St. Louis, MO) dissolved in phos-
phate buffered saline, pH 7.4 (PBS, Kantonsapotheke
Zürich, Zurich, Switzerland). In the MPO-stop-solution,
2.7 μg catalase (Sigma-Aldrich) was dissolved in 50 ml
PBS. Lung, kidney, liver and spleen proteins were ex-
tracted as described for heart protein extracts. Five μl of
protein extract was added to a 96-well clear microtiter
plate (Nunc, Thermo Fisher, Waltham, MA, USA). Three
hundred μl MPO reagent was added to each well and
stopped with MPO-stop-solution after two minutes of in-
cubation using a multichannel pipette. Absorption of
transmitted light was determined at 470 nm (Infinite
M200 Pro, Tecan, Männedorf, Switzerland). MPO-activity
(A) was then calculated using an extinction coefficient (ε)
of 26.6*mM−1*cm−1 and the formula: A = (dE*V)/(ε*d*v),
with A = activity, V = total volume in assay, v = volume of
protein extract, d = distance, ε = extinction coefficient, dE =
extinction difference = extinctionfinal – extinctionbeginning.
Enzyme activity was corrected for the amount of pro-
tein in the extract. Results are presented as U/g tissue
protein. One unit is defined as the amount of enzyme
consuming 1 μmol H2O2 per minute.
Serum nitrate/nitrite (NOx) measurement
One hundred μl rat sera was mixed with 100 μl 10% tri-
chloracetic acid (TCA, Sigma Aldrich) and allowed to sit
on ice for 15 minutes in the dark before being centri-
fuged for 5 minutes at 4°C and 16,100 g. Concentration
of serum NOx was determined using a nitric oxide
analyzer (NOATM280, Sievers Instruments, Inc., Boulder,
CO, USA) as described previously [32,33] .
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Cardiac adenosine triphosphate measurement
Frozen heart tissue was homogenized in radioimmuno-
precipitation (RIPA) buffer (Boston BioProducts, Ashland,
MA, USA) supplemented with proteinase-inhibitor cock-
tail, phenylmethanesulfonyl fluoride (200 mM), sodium
fluoride (1 mM) and sodium orthovanadate (1 mM), all
from Sigma Aldrich (St. Louis, MO, USA) using a Kinematica
Polytron homogenizer (Fisher Scientific, Pittsburgh, PA,
USA). After 10 brief sonication pulses (Sonic Dismembra-
tor 100, Fisher Scientific, Hampton, NH,USA), the sam-
ples were centrifuged for 15 minutes at 4°C and 16,100 g
in a microcentrifuge (Eppendorf 5415R, Eppendorf AG,
Hamburg, Germany). The supernatant was collected and
total protein concentration was determined by DC Protein
Assay (Bio-Rad, Hercules, CA, USA) using immunoglobu-
lin G (IgG) (Bio-Rad) for the calculation of the standard
curve. Adenosine triphosphate (ATP) levels were deter-
mined with an ATP determination kit (Life Technologies,
Carlsbad, CA, USA) according to the manufacturer’s
protocol.
Determination of mitochondrial complexes by Western
blot
Heart tissue lysates were diluted in 6x Laemmli sample
buffer (Boston Bioproducts) to a final concentration of 1x
together with dithiothreitol (DTT, 30 μM, Sigma Aldrich).
The samples were heated to 50°C for five minutes and
20 μg of protein was loaded on a 10% sodium dodecyl-
sulfate polyacrylamide gel (SDS-PAGE), and then sepa-
rated and blotted on a nitrocellulose membrane (Bio-Rad)
as previously described [34]. After blocking (5% bovine
serum albumin, BSA in tris-buffered saline plus 0.1%
TWEEN-20, Sigma; TBST) for one hour at room tem-
perature (RT), membranes were probed over night at 4°C
with MitoProfile total OXPHOS rodent antibody-cocktail
(detecting mitochondrial complexes I-V; Abcam, Eugene,
OR, USA, 1:1000). After three five-minute washes with
TBST, the membranes were incubated with a horseradish-
peroxidase (HRP) conjugated secondary antibody at RT
for one hour. After four washes with TBST (five minutes
each), HyBlot CL film (Denville, South Plainfield, NJ,
USA) was exposed to membranes following incubation
with SuperSignal Pico ECL solution (Fisher Scientific).
Glyceraldehyde-3-phosphate dehydrogenase protein level
(GAPDH, antibody from Santa Cruz Biotechnology, Santa
Cruz, CA, USA) was used as a loading control.
Statistical analyses
Values are expressed as mean (± SD). Statistical analysis
was performed with GraphPad Prism 6.0 (GraphPad, La
Jolla, CA, USA) and R 3.0.2 (R Development Core Team,
R Foundation for Statistical Computing, Vienna, Austria).
First, normal distribution of the data was tested with a
Shapiro-Wilk test. Comparisons between groups with
normally distributed data were carried out using a two-
tailed student’s t-test (two groups) or analysis of variance
(ANOVA) with Tukey’s post hoc test (≥3 groups) or a
Mann–Whitney U-Test (two groups), or by Kruskal-
Wallis test with Dunn’s multiple comparison correction
(≥3 groups) for not-normally distributed data. A P value
<0.05 was considered to be statistically significant. Survival
was analyzed by a log-rank test, heart rate and blood pres-
sure using a mixed linear model with heart rate and blood
pressure as response variables, group and time as fixed ef-
fects, and individuals as random effects. Multiple compari-
sons of means in this linear model were performed with a
Tukey post hoc test.
Samples of animals that had to be sacrificed for ethical
reasons (see above) were collected and assigned to the
next following time point.
Results
Survival
Ninety-four percent (17 out of 18) of animals in the
sham groups (isoflurane-sham and propofol-sham) sur-
vived the entire 24-hour experimental period. In septic
animals (CLP) sedated with any of the three volatile
agents, overall survival rate was 65% (22 out of 34). Sur-
vival in the isoflurane + CLP (55%, 7 out of 11), sevoflur-
ane + CLP (67%, 8 out of 12) and desflurane + CLP (73%,
8 out of 11) groups was not significantly different from
the two sham groups. However, mean survival of septic
animals sedated with propofol (CLP-propofol) at 12 hours
was significantly reduced compared to all other groups
(P <0.001, Figure 1). Intralipid application did not affect
mortality in isoflurane + CLP animals (Additional file 1).
Development of metabolic acidosis
Base excess (BE) rather than pH was chosen in order to
correct for possible ventilation differences between the an-
imals. In all CLP groups as well as in the propofol-sham
group, BE decreased. Development of acidosis in the pro-
pofol + CLP group was faster and more pronounced when
compared to all other groups (Figure 2). At 6, 12 and 18
hours, BE was significantly lower in the propofol + CLP
group in comparison to all septic groups sedated with
volatile anesthetics (6 hours: −12.0 ± 3.9 mEq/L, all
P <0.01, 12 hours: −16.1 ± 4.6 mEq/L, all P <0.001 and 18
hours: −20.7 ± 2.0 mEq/L, all P <0.01, respectively). One
animal surviving close to 24 hours in the propofol + CLP
group had a BE of −23.8 mEq/L. Application of intrali-
pid had no influence on the development of acidosis
(Additional file 2).
Interestingly, sham-operated animals sedated with pro-
pofol developed acidosis as well, whereas animals sedated
with isoflurane did not (Figure 2). These BE differences
were statistically significant after 18 and 24 hours (−11.5 ±
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3.1 versus -3.4 ± 4.1 and −13.6 ± 3.2 versus -2.4 ± 3.9,
P <0.001 for both comparisons).
Lactate in isoflurane-sham animals was 1.08 ± 0.77 mM
after 24 hours of sedation. This value was significantly
lower than in the propofol-sham (2.50 ± 0.46 mM) and
isoflurane + CLP (2.25 ± 1.24 mM) animals (P = 0.001 and
0.004, respectively). Serum lactate also reached higher
values in propofol + CLP compared to isoflurane + CLP
animals after 12 hours (3.03 ± 0.42 versus 1.33 ± 0.31 mM,
P <0.001, Additional file 3).
Oxygenation
The oxygenation index was not significantly altered over
the course of the experiment in any of the experimental
groups (Additional file 4).
Heart rate
No difference in heart rate was observed between septic
and sham-operated animals. However, heart rate was
consistently higher in all isoflurane-sedated animals:
isoflurane-sham animals had an average heart rate of
383 ± 57 beats per minute (bpm) versus propofol-sham
animals 328 ± 47 bpm (P <0.001). The same range of
values was observed in septic animals: the isoflurane +
CLP group presented with a heart rate of 372 ± 69 bpm
compared to the propofol + CLP (313 ± 64 bpm; P <0.001),
sevoflurane + CLP (339 ± 62 bpm; P = 0.01), and desflur-
ane + CLP (330 ± 60 bpm; P = 0.01) animals, respectively
(Figure 3 and Additional file 5).
Blood pressure
Overall, as shown in Figure 4 and Additional file 6,
lower blood pressure values could be found in desflur-
ane + CLP (70 ± 12 mmHg) and propofol + CLP (67 ± 16
mmHg; P = 0.03) rats compared to isoflurane + CLP ani-
mals (79 ± 18 mmHg; P <0.01 for both comparisons).
Intravenous fluid administration and hematocrit values
Isoflurane-sham and propofol-sham animals received simi-
lar amounts of NaCl over the course of the experiment
(23.5 ± 2.2 ml versus 23.9 ± 2.4 ml). Fluid administration in
septic animals was significantly higher (42.9 ± 14.5 ml,
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Figure 1 Survival. Twenty-four hour survival of rats following cecal ligation and puncture (CLP) or sham operation under continuous sedation
with propofol, isoflurane, sevoflurane or desflurane and continuous mechanical ventilation. Survival was compared using the Log-rank test,
*P <0.05 versus isoflurane + CLP.
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Figure 2 Acidosis. Development of acidosis, measured by base excess after 0, 6, 12, 18 and 24 hours in septic and sham-operated rats. Animals
were under continuous sedation with propofol, isoflurane, sevoflurane or desflurane and under continuous mechanical ventilation. Values represent
mean ± standard deviation. *P <0.05 versus isoflurane + CLP. CLP, cecal ligation and puncture.
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38.8 ± 15.7 ml and 53.7 ± 20.5 ml for isoflurane + CLP,
sevoflurane + CLP and desflurane + CLP, P = 0.005, 0.03
and P <0.001 versus isoflurane-sham). Propofol + CLP ani-
mals had an even higher fluid requirement (60.2 ± 17.0 ml
versus 11.8 ± 3.5 ml after 12 hours compared to isoflurane +
CLP, P <0.001). Hematocrit values at the end of the ex-
periment were similar in all animal groups with values of
24.3 ± 3.9 (isoflurane-sham), 24.5 ± 2.5 (propofol-sham),
24.2 ± 4.4 (isoflurane +CLP at 24 hours), 23.0 ± 2.1 (isoflur-
ane + CLP at 12 hours), 23.2 ± 3.5 (sevoflurane + CLP),
26.7 ± 3.2 (desflurane +CLP) and 23.2 ± 3.5 (propofol +CLP).
Kidney and liver damage marker profiles
ALT was increased in the sevoflurane + CLP (59.3 ± 24.7
U/l) and the isoflurane + CLP (68.5 ± 38.7 U/l) groups
compared to sham-operated isoflurane-treated animals
(33.8 ± 7.6 U/l), P = 0.03 and P = 0.03, respectively; Table 1).
No differences in AST were detected. After 12 hours,
AP in propofol + CLP treated animals was 264 ± 185 U/
l compared to 187 ± 46 U/l in isoflurane + CLP animals
(P <0.001, Table 1).
After 24 hours, bilirubin was increased in propofol-sham
animals (0.176 ± 0.055 mg/dl) compared to isoflurane-
sham (0.109 ± 0.027 mg/dl; P = 0.03, Table 1). Blood urea
nitrogen and creatinine were higher in all septic compared
to isoflurane-sham animals (all P <0.05, Table 1).
Blood endotoxin concentration
In septic animals, a 1.7-, 2.0- and 2.0-fold increase of
endotoxin concentration in the blood was observed after
24 hours in isoflurane, sevoflurane and desflurane-treated
rats (P = 0.05, 0.001 and 0.001 versus isoflurane-sham, re-
spectively; Figure 5A). Propofol-sham animals had 2.7-
times higher endotoxin levels in their blood compared to
the isoflurane-sham group (P <0.001, Figure 5A). Intralipid
increased blood endotoxin levels by 42% in isoflurane +
intralipid + CLP versus isoflurane + CLP animals (P = 0.01,
Additional file 7). At 12 hours, endotoxin concentration
increased two-fold in septic animals sedated with propofol
compared to those sedated for 12 hours with isoflurane
(P <0.001, Figure 5B).
Blood cytokines
Blood cytokine levels were higher in septic animals. In rats
sedated with propofol, even more cytokines were found.
TNF-α was increased in the propofol-sham (89 ± 56 pg/ml),
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Figure 3 Heart rate. Effect of continuous sedation with propofol, isoflurane, sevoflurane or desflurane on heart rate (beats per minute, bpm) in
septic (CLP) and sham-operated rats. Values represent mean ± standard deviation. CLP, cecal ligation and puncture.
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Figure 4 Blood pressure. Effect of continuous sedation with propofol, isoflurane, sevoflurane or desflurane on mean arterial blood pressure in
septic (CLP) and sham-operated rats. Values represent mean ± standard deviation. CLP, cecal ligation and puncture.
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isoflurane + CLP (282 ± 291 pg/ml), and sevoflurane +
CLP (89 ± 70 pg/ml) groups compared to isoflurane-sham
(23 ± 15 pg/ml; P = 0.01, P <0.001 and P = 0.03, respect-
ively). Increased values for IL-1β, IL-6, IL-10 and CXCL-2
were also observed in all volatile anesthetic sepsis groups
compared to isoflurane-sham animals (all P <0.03, Table 2),
and IFN-γ was increased in isoflurane + CLP compared to
isoflurane-sham animals (134.2 ± 131.9 versus 12.4 ± 12.2
pg/ml, P = 0.04; Table 2). After 12 hours, septic animals
sedated with propofol showed increased levels of TNF-α,
IL-1β, IL-10, CXCL-2, IFN-γ and HMGB-1 compared to
animals sedated with isoflurane (all P <0.05; Table 2).
Creatine kinase values
To exclude propofol infusion syndrome, serum CK levels
were determined. Due to high inter-individual differ-
ences, no significant difference could be detected in the
24 hour-animals. Values from sham animals seemed to
be lower than from CLP groups (Additional file 8: Figure
A).
At 12 hours, CK was similar in the CLP groups: 1115 ±
786 U/L in isoflurane + CLP and 996 ± 838 U/L in propo-
fol + CLP animals (Additional file 8: Figure B).
Tissue neutrophil content in lung, spleen, kidney and liver
Sepsis increased MPO activity in the lung, but the observed
difference only reached statistical significance between the
isoflurane + CLP and the isoflurane-sham groups (1.7-fold
increase, P = 0.02). Also, propofol by itself increased
MPO activity in the lung: propofol-sham animals re-
vealed a 2.3-fold increase in MPO activity compared to
isoflurane-sham (P <0.001), and after 12 hours, CLP-
propofol animals showed a 1.9-fold increase in MPO activity
compared to isoflurane +CLP animals (P <0.001, Table 3).
In the spleen, MPO activity was 2.1-times higher in
the propofol-sham versus isoflurane-sham animals at 12
Table 1 Serum liver and kidney marker profile at 24 and 12 hours
AP [U/l] ALT [U/l] AST [U/l] Bilirubin [mg/dl] BUN [mg/dl] Creatinine [mg/dl]
24-hour animals (sham and CLP)
isoflurane-sham 126(± 20) 33.8(± 7.6) 93(± 33) 0.109(± 0.027) 38.8(± 14.8) 0.33(± 0.13)
propofol-sham 367(± 161)*** 35.6(± 6.1) 78(± 17) 0.176(± 0.055)* 59.4(±12.0) 0.72(± 0.32)
Isoflurane +CLP 253(± 117)* 68.5(± 38.7)* 210(± 177) 0.208(± 0.089)** 71.4(± 21.2)* 0.80(± 0.28)*
Sevoflurane + CLP 232(± 53)** 59.3(± 24.7)* 172(± 107) 0.186(± 0.073)* 73.1(± 33.0)** 0.88(± 0.52)**
Desflurane + CLP 262(± 60)*** 42.1(± 16.1) 107(± 55) 0.151(± 0.024) 66.7(± 17.0)* 0.86(± 0.38)*
12-hour CLP animals
Isoflurane + CLP 187(± 46) 73.6(± 34.3) 222(± 136) 0.164(± 0.051) 58.6(± 12.7) 0.53(± 0.19)
propofol + CLP 264(± 185)## 67.3(± 42.2) 168(± 109) 0.255(± 0.104)# 43.3(± 22.4) 0.85(± 0.47)
*P <0.05, **P <0.01, ***P <0.001 versus sham-isoflurane; #P <0.05, ##P <0.001 versus isoflurane + CLP 12 hour. ALT, alanine aminotransferase; AP, alkaline phosphatase;
AST, aspartate aminotransferase; BUN, blood urea nitrogen; CLP, cecal ligation and puncture.
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Figure 5 Blood endotoxin concentration. Effect of continuous sedation with propofol, isoflurane, sevoflurane or desflurane on blood
endotoxin levels in septic (CLP) and sham-operated rats. Animals were under continuous sedation and mechanical ventilation for 24 hours (A) or
12 hours (B). Values represent mean ± standard deviation. *P <0.05 versus isoflurane-sham (A) or isoflurane + CLP (B), respectively. CLP, cecal
ligation and puncture.
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hours (P = 0.04, Table 3). No differences were observed
in the kidney. In the liver, MPO activity was below the
limit of detection.
Blood NOx values
Similar levels of NOx were found in the blood of all ani-
mals. The values for the different groups after 24 hours
were 73.88 (±15.85), 25.16 (±9.72), 68.36 (±51.56), 17.91
(±6.15) and 251.80 (±141.50) for isoflurane-sham, propofol-
sham, isoflurane + CLP, sevoflurane + CLP and desflurane +
CLP, respectively (Additional file 9).
Cardiac ATP content
ATP levels in cardiac tissue lysates were not significantly
different among the various treatment groups.
Cardiac mitochondria complexes
In the 24-hour groups, no differences in expression of
mitochondrial complexes were detected. Similar results
were found after 12 hours. However, while no differences
in mitochondrial complexes I, II, III and V were ob-
served, complex IV (cytochrome c oxidase) was increased
by 3.3 (±1.6) fold in propofol + CLP compared to isoflur-
ane + CLP animals after 12 hours of sedation (P = 0.03,
Additional file 10).
Discussion
Long-term sepsis model
With this work, we describe a newly developed experi-
mental model of rodent sepsis lasting up to 24 hours
with sedation and mechanical ventilation. The current
study provides compelling evidence to suggest that: 1) sed-
ation of septic rats with volatile anesthetics (isoflurane,
sevoflurane or desflurane) tremendously reduces mortality
compared to rats sedated with propofol, and 2) in the set-
ting of prolonged intra-abdominal sepsis, propofol may ac-
tually hasten physiological deterioration. Sedation with
volatile anesthetics leads to a slower development of acid-
osis, reduced expression of pro-inflammatory cytokines,
and reduced levels of plasma endotoxin compared to sed-
ation with propofol.
Our model employed continuous sedation, along with
mechanical ventilation, arterial blood pressure and heart
rate monitoring, as well as fluid resuscitation, and, thus,
it very closely resembled the clinical situation in an ICU.
The long observation time not only allowed for deter-
mination of surrogate markers, but also the evaluation
of a strong outcome parameter such as survival, which is
the most important aspect within the clinical picture of
severe polymicrobial sepsis.
Sedation and base excess
In interpreting the mortality data, the question of cause
of death arises. One explanation could be the more accen-
tuated impairment of the acid base balance in septic ani-
mals. Comparing the propofol + CLP group with animals
Table 2 Serum cytokines at 24 and 12 hours
TNF-α
[pg/ml]
IL-1α
[pg/ml]
IL-1β
[pg/ml]
IL-6
[ng/ml]
IL-10
[pg/ml]
CXCL2
[ng/ml]
IFN-γ
[pg/ml]
HMGB-1
[ng/ml]
24 hour animals
(sham and CLP)
Isoflurane-sham 22.7(± 14.6) 13.9(± 9.2) 143(± 125) 4(± 3) 151(± 95) 0(± 0) 12.4(± 12.2) 0.0(± 0.0)
Propofol-sham 88.7(± 55.9)* 16.7(± 10.3) 368(± 112) 46(± 23) 605(± 265) 2(± 2) 79.3(± 119.4) 0.0(± 0.0)
Isoflurane + CLP 281.9(± 291.3)*** 94.9(± 124.7) 510(± 418)* 220(± 179)*** 1717(± 1567)*** 38(± 42)*** 134.2(± 131.9)* 13.5(± 22.3)
Sevoflurane + CLP 89.1(± 70.5)* 30.6(± 29.1) 459(± 219)** 65(± 33)** 774(± 402)** 15(± 13)*** 50.5(± 53.3) 4.0(± 7.2)
Desflurane + CLP 61.8(± 31.0) 42.9(± 54.5) 537(± 325)** 69( 32)** 781(± 369)** 24(± 17)*** 83.4(± 93.6) 0.0(± 0.0)
12 hour
CLP animals
Isoflurane + CLP 141.4(± 78.8) 24.0(± 17.8) 325(± 217) 45(± 16) 267(± 109) 3(± 3) 3.6(± 0.0) 0.0(± 0.1)
Propofol + CLP 549.9(± 440.2) 165.8(± 196.1)### 1446(± 954)### 126(± 117) 1240(± 1148)# 41(± 55)# 541.9(± 567.7)# 10.1(± 10.7)#
*P <0.05, **P <0.01, ***P <0.001 versus sham-isoflurane; #P <0.05, ###P <0.001 versus isoflurane + CLP 12 hour. CLP: cecal ligation and puncture; CXCL2: chemokine
(c-x-c motif) ligand 2; HMGB-1: high mobility group protein-1; IFN-γ: interferon gamma; IL-1α: interleukin-1alpha; IL-1β: interleukin-1beta; IL-6: interleukin-6; IL-10:
interleukin-10; TNF-α: tumor necrosis factor-alpha.
Table 3 MPO activity various tissues
MPO activity [U/g] Lung Kidney Spleen
24 hour animals
(sham and CLP)
isoflurane-sham 27.08(± 10.23) 1.20(± 0.39) 4.77(± 2.56)
propofol-sham 63.03(± 13.34)*** 1.40(± 0.64) 10.12(± 6.75)*
isoflurane + CLP 44.79(± 18.11)* 2.07(± 0.67) 4.77(± 2.56)
sevoflurane + CLP 41.27(± 8.68) 1.53(± 0.57) 7.35(± 4.25)
desflurane + CLP 38.00(± 9.90) 0.87(± 0.24) 8.61(± 3.23)
12 hour CLP animals
isoflurane + CLP 28.48(± 11.42) 0.78(± 0.26) 5.94(± 3.51)
propofol + CLP 54.20(± 9.75)### 0.91(± 0.21) 7.17(± 3.90)
*P <0.05, ***P <0.001 versus sham-isoflurane; ###P <0.001 versus isoflurane + CLP
12 hour. CLP: cecal ligation and puncture; MPO: myeloperoxidase.
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sedated with volatile anesthetics, it is evident that BE is
significantly worse in the presence of propofol. The
hemodynamic situation as another important factor likely
influencing survival cannot be interpreted, as low blood
pressure values were counteracted with a pre-defined fluid
resuscitation protocol. Therefore, one could assume that
metabolic acidosis as a consequence of sepsis in the pro-
pofol + CLP group further accentuated the persistent
propofol-induced vasoplegia leading to severe hypotension
with subsequent organ hypoperfusion and, finally, mal-
function of critical organs [35]. A relative ‘intoxication’
with propofol in comparison to the volatile anesthetics
can be excluded as depth of sedation was carefully ob-
served and adjusted using indirect measures. Therefore,
the same depth of anesthesia can be assumed in all animal
groups. Also, occurrence of propofol infusion syndrome
seems rather unrealistic as serum CK values were compar-
able in both sedation groups.
Interestingly, propofol reduced BE independent of the
presence of sepsis. A similar phenomenon was observed
in pediatric patients undergoing heart catheterization
where propofol led to a decrease in BE and pH without
a rise in blood lactate levels [36]. Ypsilantis et al. re-
ported more pronounced acidosis and 100% mortality in
healthy rabbits upon an aimed 48 hour exposure to pro-
pofol compared to sevoflurane [37].
Intralipid and base excess
As a next step, we carefully tested the hypothesis that
the lipid emulsion per se could be the causative agent in
the intravenous propofol solution. However, data clearly
showed that administration of intralipid alone did not
correlate with metabolic acidosis. Propofol infusion syn-
drome could be discussed as well, although reported
serum values of lactate for this disease in humans are
much higher than the values we observed in our study
[38]. Therefore, we can conclude that propofol itself, by
inducing metabolic acidosis as a first hit, may set the
stage for a second injury such as sepsis that can result in
extreme deterioration of the acid–base balance and fi-
nally death of the animals.
As indicators for circulation, we monitored heart rate
and blood pressure continuously. As rats are prone to
right heart failure, continuous PEEP was applied and re-
cruitment maneuvers were conducted every thirty mi-
nutes [39]. Thus, in our experiment, animals may have
died from insufficient circulation due to hypotension as
a result of heart failure, vasoplegia or hypovolemia. ATP
levels were similar in all groups and a fluid replacement
protocol was followed; therefore, we would predict that
the cardiac energy supply was not a limiting factor for
survival. Acidosis, however, may affect cardiac function
[40,41] and tone of the vascular system [42] resulting in
low output failure and relative hypovolemia.
Volatile anesthetics and organ dysfunction in sepsis
With regard to mortality, there were no differences
among the volatile anesthetics tested. Considering surro-
gate markers such as inflammatory mediators, however,
one could argue that sevoflurane may be superior to
desflurane and isoflurane, although larger studies aimed
at testing this hypothesis would be needed.
According to the liver and kidney serum markers of
organ damage obtained from the animals in our study,
mortality was not primarily caused by acute liver or kid-
ney failure. However, it is interesting to note that that
AST and ALT levels were higher in sevoflurane and iso-
flurane treated animals compared to desflurane treated an-
imals. Inorganic fluoride ion concentrations are known to
increase during isoflurane [43] and sevoflurane [44]
anesthesia compared to desflurane anesthesia, which may
have had an impact on liver function as well as on AST
and ALT release [45].
Previous studies have reported a reduction of cyto-
kines in septic animals under the influence of isoflurane
[20,22,46,47], sevoflurane [19,20] and desflurane [20,23]
which we also observed. Interestingly, there are several
studies showing possible anti-inflammatory effects of
propofol [48-50]. However, most of these studies did not
directly compare propofol exposure to treatment with a
volatile anesthetic agent [48,50]. It is also not clear in
these studies which propofol formulation was used [48,51]
or whether it contained ethylenediaminetetraacetic acid
(EDTA) [49,50] which is known to account for many of
the observed anti-inflammatory effects of propofol due to
its ability to destabilize the bacterial wall [52]. As our goal
was to investigate the potential immunomodulatory effect
of sedatives and not of additives, we utilized a propofol
formulation without EDTA in our study. Interestingly,
HMGB-1, a cytokine with a negative predictive value on
survival in sepsis [53], was indeed significantly increased
in propofol + CLP rats, that is, in the animals that actu-
ally succumbed earlier as compared to isoflurane + CLP
animals.
Plasma endotoxin and innate immunity
The elevated level of endotoxin in propofol-sedated rats
compared to the volatile anesthetic groups suggests that
propofol may increase host susceptibility to infection, sup-
press bacterial clearance, or increase the release of lipo-
polysaccharide (LPS) into the bloodstream after increased
bacterial translocation or growth. Another consideration
is that bacterial growth may be enhanced by lipid formula-
tions, a phenomenon which is known to be prevented in
the presence of EDTA in the propofol formulation [54].
To avoid contamination, strict aseptic technique was ap-
plied during our experiments. For each experiment, a new
bottle of propofol was used and propofol syringes were re-
placed every eight hours. Given the overall higher levels of
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serum cytokines in propofol-treated animals, our results
suggest that the reaction of the animals’ immune system
remained intact and that more bacteria may have led to
more endotoxin and a more pronounced cytokine storm.
[55] However, this does not exclude a propofol effect on
innate immunity. Activation of inducible NO-synthase
(iNOS) may lead to an increase in superoxide production
[56] which is considered to be an important defense
mechanism against bacteremia, whereas inhibition of
iNOS may exacerbate an infection [57]. It has been sug-
gested that propofol exposure may inhibit early superoxide
production in neutrophils [58]. If this had been the reason
for the increase in mortality in our setting, we would have
expected lower values of serum nitric oxide (NO). How-
ever, serum concentrations of NOx did not differ signifi-
cantly among the groups, and, thus, NOx is likely not
responsible for the defect in immune defense or for pro-
moting bacterial growth in animals sedated with propofol.
The effect of propofol on gut barrier function in septic
or in healthy subjects is not known. Long-term application
of intravenous lipid solutions – the carrier substrate for
propofol – however, reduces intestinal cell proliferation,
increases intestinal epithelial apoptosis and reduces gut
barrier function [59]. This might explain the increased
endotoxin levels in our animals exposed to intralipid. In-
tegrity of the intestinal barrier may have been further re-
duced by acidosis [60] due to propofol application. We,
therefore, hypothesize that the gut barrier might be mark-
edly impaired in the presence of propofol. A recent study
suggests that propofol might have a protective effect on
the gut barrier in rats following burn injury [61]. However,
in this particular study, direct comparison of propofol and
volatile anesthetics was not performed and, further, it is
not clear which propofol formulation was used.
Our study does not clearly answer the question whether
we are able to show improved survival by volatile anes-
thetics due to positive immunomodulation or if we are
demonstrating detrimental effects of propofol on microcir-
culation. It is described that propofol affects microcircula-
tion, for example, in the gastric mucosa [62]. It is further
known that differences in microcirculation account for
organ failure and eventually also death in septic patients
[63]. Maybe a second intravenous agent, such as midazo-
lam, could have addressed this issue. Despite these open
questions, volatile anesthetics seem to be the better option
in our model.
We are aware that performing sedation with volatile
anesthetics is an off-label use in many countries and is
not considered a standard regimen [24]. However, these
drugs may provide benefits such as no organ-dependent
degradation, minimal metabolism and short titration and
awakening times [64].
A definite strength of our study design was the direct
comparison of the effect of clinically relevant sedatives
with volatile anesthetics on the course of sepsis. This is
the first study to compare long-term application of seda-
tives during simultaneous mechanical ventilation, and
thus, is more likely to reflect the situation of a septic pa-
tient in the ICU than studies comparing short-term ap-
plication of sedatives before or after onset of an injury.
To limit the number of variables in the current study,
we omitted the use of antibiotics and vasopressors,
which at the same time could be a limitation of our
study. A further limitation of this study might be the fact
that rats need higher doses of propofol to achieve light
sedation compared to humans [65], probably due to
higher propofol clearance rates [66], whereas the MAC
values of volatile anesthetics are similar [67].
Conclusions
In summary, the results of our study may be of signifi-
cant clinical relevance as they further support volatile
anesthetics as the sedative agent of choice for septic pa-
tients. Greater implementation of the use of volatile
agents in the ICU setting may significantly affect the
course of inflammation, the microbial load, and poten-
tially, the survival of septic patients who currently ex-
hibit extremely high mortality rates. Clinical trials are
needed to confirm these results.
Key messages
 This is the first model of prolonged mechanical
ventilation in severe sepsis (up to 24 hours)
comparing beneficial and detrimental effects of
various sedative strategies
 The commonly used clinical sedative propofol is
associated with increased blood endotoxin levels, a
stronger inflammatory reaction, a more pronounced
acidosis and, importantly, with poor survival.
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